Treatment of advanced refractory sarcomas with ifosfamide and etoposide combination chemotherapy

Cancer Investigation

Volumn 16, Issue 5, 1998, Pages 297-302

  Yalçin, Şuayib ^a   Güllü, Ibrahim ^a   Barişta, Ibrahim ^a   Tekuzman, Gülten ^a   Özişik, Yavuz ^a   Çelik, Ismail ^a   Kars, Ayşe ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MESNA; VINCRISTINE;

ADULT; AGED; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER GRADING; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HEMORRHAGIC CYSTITIS; HUMAN; MALE; NAUSEA; PATIENT CODING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SARCOMA; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME; TUMOR CLASSIFICATION; VOMITING;

EID: 2642626630     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909809084647     Document Type: Article

References (24)

1. Boring CC, Squires TS, Tong T: Cancer statistics, 1992. CA 42:19-38, 1992.
2. Borden EC, Amato DA, Rosenbaum C, et al: Randomized comparison of three adriamycin regimens for metastatic soft tissue carcinomas. J Clin Oncol 5:840-850, 1987.
3. O'Bryan RM, Luce JK, Talley RW: Phase II evaluation of adriamycin in human neoplasia. Cancer 32:1-8, 1973.
4. Antman KH, Ryan L, Elias A, et al: Response to ifosfamide and mesna: 124 previously treated patients with metastatic unresectable sarcoma. J Clin Oncol 7:126-131, 1989.
5. Stuart-Harris R, Harper PG, Kaye SB, et al: High dose infusion with mesna in advanced soft tissue sarcoma. Cancer Treat Rev 10:163-164, 1983.
6. Yap BS, Sinkovics JG, Benjamin RS, et al: Survival and relapse patterns of complete responders in adults with advanced soft tissue sarcomas. Proc Am Assoc Cancer Res 20:352, 1979.
7. Demetri CD, Elias AD: Results of single agent and combination chemotherapy for advanced soft tissue sarcomas. Hematol Oncol Clin North Am 9:765-785, 1995.
8. van Oosterom AT, Verweij J: New drugs for the treatment of sarcomas. Hematol Oncol Clin North Am 9:909-925, 1995.
9. Güllü IH, Yalçin Ş, Tekuzman G, et al: High dose ifosfamide by infusion with mesna in advanced refractory sarcomas. Cancer Invest 14:239-242, 1996.
10. Slayton RE, Blessing JA, Angel C, et al: Phase II trial of etoposide in the management of advanced and recurrent leiomyosarcoma of the uterus: A Gynecologic Oncology Group Study. Cancer Treat Rep 71:1303-1304, 1987.
11. O'Dwyer PJ, Leyland-Jones B, Alonso MT, et al: Etoposide (VP-16-213): current status of an active anticancer drug. N Engl J Med 312:692-700, 1985.
12. Chard RL, Krivit W, Bleyer WA, et al: Phase II study of VP-16-213 in childhood malignant disease: a Children's Cancer Study Group report. Cancer Treat Rep 63:1755-1759, 1979.
13. Brade WP, Herdrich K, Varini M: Ifosfamide: pharmacology, safety and therapeutic potential. Cancer Treat Rev 12:1-47, 1985.
14. Loehrer PJ, Lauer R, Roth BJ, et al: Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med 109:540-546, 1988.
15. Wellens W, Donhuijsen-Ant R, Habets L, et al: Therapy progredienter sarkoma mit etoposide und ifosfamide. Aktuelle Onkologie 4:159-164, 1981.
16. Miser JS, Kinsella TJ, Timothy J, et al: Ifosfamide with mesna uroprotection and etoposide: An effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol 5:1191-1198, 1987.
17. Edmonson JH, Buckner JC, Long HJ, et al: Phase II study of ifosfamide-etoposide-mesna in adults with advanced nonosseous sarcomas. J Natl Cancer Inst 81:866-870, 1989.
18. Issels RD, Prenninger SW, Nagele A, et al: Ifosfamide plus etoposide combined with regional hyperthermia in patients with locally advanced sarcomas: A phase II study. J Clin Oncol 8:1818-1829, 1990.
19. Issels RD, Mittermüller J, Gerl A, et al: Improvement of local control by regional hyperthermia combined with systemic chemotherapy (ifosfamide plus etoposide in advanced sarcomas: updated report of 65 patients). J Cancer Res Clin Oncol 117 (Suppl 4):141-147, 1991.
20. Kung HF, Pratt BC, Vega AR, et al: Ifosfamide/etoposide combination in the treatment of recurrent malignant solid tumors of the childhood. Cancer 71:1898-1902, 1993.
21. Skubitz MK, Hamdan H, Thompson R: Ambulatory continuous infusion of ifosfamide with oral etoposide in advanced sarcomas. Cancer 72:2963-2969, 1993.
22. Blair CS, Zalupski MM, Baker LH: Ifosfamide and etoposide in the treatment of advanced soft tissue sarcomas. Am J Clin Oncol 17:480-484, 1994.
23. Linke KA, Hays C, Burgess MA, et al: Oral etoposide results in previously treated soft tissue sarcoma patients. Proc Am Assoc Cancer Res 34:208, 1993.
24. Licht JD, Mazanet R, Loehrer PJ, et al: Phase IV trial of daily oral etoposide in the treatment of advanced soft tissue sarcoma. Cancer Chemother Pharmacol 43:79-80, 1994.